Killestein J - Search Results

1

Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.

Coerver EME, Bourass A, Wessels MHJ, van Kempen ZLE, Jasperse MMS, Tonino BAR, Barkhof F, Mostert J, Uitdehaag BMJ, Killestein J, Strijbis EMM. Coerver EME, et al. Among authors: killestein j. Mult Scler Relat Disord. 2023 Jun;74:104706. doi: 10.1016/j.msard.2023.104706. Epub 2023 Apr 3. Mult Scler Relat Disord. 2023. PMID: 37068370 Free article.

2

MS functional composite: relation to disease phenotype and disability strata.

Kalkers NF, de Groot V, Lazeron RH, Killestein J, Adèr HJ, Barkhof F, Lankhorst GJ, Polman CH. Kalkers NF, et al. Among authors: killestein j. Neurology. 2000 Mar 28;54(6):1233-9. doi: 10.1212/wnl.54.6.1233. Neurology. 2000. PMID: 10746590

3

Quality of life during the first 6 months of interferon-beta treatment in patients with MS.

Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Arnoldus JH, et al. Among authors: killestein j. Mult Scler. 2000 Oct;6(5):338-42. doi: 10.1177/135245850000600508. Mult Scler. 2000. PMID: 11064444 Clinical Trial.

4

Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.

Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Killestein J, et al. Mult Scler. 2001 Jun;7(3):145-50. doi: 10.1177/135245850100700302. Mult Scler. 2001. PMID: 11475436

5

Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells.

Killestein J, Rep MH, Barkhof F, Roos MT, Adèr HJ, van Lier RA, Polman CH. Killestein J, et al. J Neuroimmunol. 2001 Aug 30;118(2):286-94. doi: 10.1016/s0165-5728(01)00346-0. J Neuroimmunol. 2001. PMID: 11498263 Clinical Trial.

6

TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS.

Killestein J, Kalkers NF, Meilof JF, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Neurology. 2001 Sep 25;57(6):1129-31. doi: 10.1212/wnl.57.6.1129. Neurology. 2001. PMID: 11571353

7

Seasonal variation in immune measurements and MRI markers of disease activity in MS.

Killestein J, Rep MH, Meilof JF, Adèr HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Neurology. 2002 Apr 9;58(7):1077-80. doi: 10.1212/wnl.58.7.1077. Neurology. 2002. PMID: 11940696

8

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Killestein J, et al. Neurology. 2002 May 14;58(9):1404-7. doi: 10.1212/wnl.58.9.1404. Neurology. 2002. PMID: 12011290 Clinical Trial.

9

Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.

Killestein J, Hintzen RQ, Uitdehaag BM, Baars PA, Roos MT, van Lier RA, Polman CH. Killestein J, et al. J Neuroimmunol. 2002 Dec;133(1-2):217-24. doi: 10.1016/s0165-5728(02)00373-9. J Neuroimmunol. 2002. PMID: 12446026

10

Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.

Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Eikelenboom MJ, et al. Among authors: killestein j. J Neuroimmunol. 2002 Dec;133(1-2):225-32. doi: 10.1016/s0165-5728(02)00374-0. J Neuroimmunol. 2002. PMID: 12446027

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters